What does this research mean for the field?

Human induced pluripotent stem cells (iPSCs) provide a highly productive platform for deriving clinically translatable immune cells, particularly engineered natural killer (NK) cells, for the treatment of refractory malignancies and autoimmune diseases. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the development of human induced pluripotent stem cell-derived immune cells, focusing on their therapeutic engineering and clinical translation.

August 28, 2026Stem CellsOpen Access

Immune cell development from human pluripotent stem cells

View Full Paper

Ask AI

Bookmark

Authors

LCLuisjesus S. Cruz ACAlejandro R. Castañeda DKDan S. Kaufman

Discussion

Member takes

Overview

Review demonstrates successful clinical translation of engineered pluripotent stem cell-derived natural killer cells in refractory malignancies, highlighting expanded therapeutic potential.

Key Points

To review the development of human induced pluripotent stem cell-derived immune cells, focusing on their therapeutic engineering and clinical translation.
Synthesized findings on differentiation pathways guiding human induced pluripotent stem cells (iPSCs) into diverse hematopoietic lineages.
Evaluated multiplexed gene-editing strategies and early-phase clinical applications of iPSC-derived immune cells in refractory malignancies and autoimmune diseases.
Human iPSCs reliably generate almost all human blood lineages, with iPSC-derived natural killer (NK) cells representing the most extensively clinically translated cell type.
Multiplexed gene editing at the pluripotent stage produces uniformly modified NK cells equipped with tumor-targeting CARs, cytokine support, improved trafficking, and immune evasion features.
Despite lingering challenges in deriving transplantable hematopoietic stem cells, iPSC-derived NK and T cells show growing therapeutic value in treatment-resistant conditions.

Cite This Study

Cruz et al. (2026) studied this question.

synapsesocial.com/papers/6a91468ad15324a1df3aa3bd https://doi.org/10.1093/stmcls/sxag048

View Full Paper

Ask AI

Bookmark

August 28, 2026Stem CellsOpen Access

Immune cell development from human pluripotent stem cells

View Full Paper

Ask AI

Bookmark

Authors

LCLuisjesus S. Cruz ACAlejandro R. Castañeda DKDan S. Kaufman

Discussion

Member takes

Overview

Review demonstrates successful clinical translation of engineered pluripotent stem cell-derived natural killer cells in refractory malignancies, highlighting expanded therapeutic potential.

Key Points

To review the development of human induced pluripotent stem cell-derived immune cells, focusing on their therapeutic engineering and clinical translation.
Synthesized findings on differentiation pathways guiding human induced pluripotent stem cells (iPSCs) into diverse hematopoietic lineages.
Evaluated multiplexed gene-editing strategies and early-phase clinical applications of iPSC-derived immune cells in refractory malignancies and autoimmune diseases.
Human iPSCs reliably generate almost all human blood lineages, with iPSC-derived natural killer (NK) cells representing the most extensively clinically translated cell type.
Multiplexed gene editing at the pluripotent stage produces uniformly modified NK cells equipped with tumor-targeting CARs, cytokine support, improved trafficking, and immune evasion features.
Despite lingering challenges in deriving transplantable hematopoietic stem cells, iPSC-derived NK and T cells show growing therapeutic value in treatment-resistant conditions.

Cite This Study

Cruz et al. (2026) studied this question.

synapsesocial.com/papers/6a91468ad15324a1df3aa3bd https://doi.org/10.1093/stmcls/sxag048

View Full Paper

Ask AI

Bookmark